

László Gulácsi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6838674/publications.pdf>

Version: 2024-02-01

261
papers

3,905
citations

136885

32
h-index

197736

49
g-index

295
all docs

295
docs citations

295
times ranked

4469
citing authors

#	ARTICLE	IF	CITATIONS
1	Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 399-408.	0.7	13
2	Measuring the acceptability of EQ-5D-3L health states for different ages: a new adaptive survey methodology. <i>European Journal of Health Economics</i> , 2022, 23, 1243-1255.	1.4	5
3	POSC286 Methodological Quality and Transferability of Cancer Costs within the MENA Region: A Systematic Review and Secondary Analysis of Published Data. <i>Value in Health</i> , 2022, 25, S190.	0.1	0
4	Validation of the PAM-13 instrument in the Hungarian general population 40 years old and above. <i>European Journal of Health Economics</i> , 2022, 23, 1341-1355.	1.4	7
5	Predicting Patient-Level 3-Level Version of EQ-5D Index Scores From a Large International Database Using Machine Learning and Regression Methods. <i>Value in Health</i> , 2022, 25, 1590-1601.	0.1	8
6	Comparing actuarial and subjective healthy life expectancy estimates: A cross-sectional survey among the general population in Hungary. <i>PLoS ONE</i> , 2022, 17, e0264708.	1.1	2
7	Disease-Related Costs Published in The Middle East and North Africa Region: Systematic Review and Analysis of Transferability. <i>Pharmacoeconomics</i> , 2022, 40, 587-599.	1.7	9
8	Disease burden of patients with pemphigus from a societal perspective. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 77-86.	0.7	9
9	Validation of the Hungarian version of the CarerQoL instrument in informal caregivers: results from a cross-sectional survey among the general population in Hungary. <i>Quality of Life Research</i> , 2021, 30, 629-641.	1.5	6
10	Subjective expectations regarding longevity and future health: a cross-sectional survey among patients with Crohn's disease. <i>Colorectal Disease</i> , 2021, 23, 105-113.	0.7	2
11	A biotechnológia inkubátorja. <i>Hungarian Statistical Review</i> , 2021, 99, 512-540.	0.0	1
12	Self-Reported Waiting Times for Outpatient Health Care Services in Hungary: Results of a Cross-Sectional Survey on a National Representative Sample. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 2213.	1.2	3
13	Outcomes of Digital Biomarker-Based Interventions: Protocol for a Systematic Review of Systematic Reviews. <i>JMIR Research Protocols</i> , 2021, 10, e28204.	0.5	17
14	Comparing the measurement properties of the ICECAP-A and ICECAP-O instruments in ages 50-70: a cross-sectional study on a representative sample of the Hungarian general population. <i>European Journal of Health Economics</i> , 2021, 22, 1453-1466.	1.4	4
15	Development of Population Tariffs for the ICECAP-A Instrument for Hungary and their Comparison With the UK Tariffs. <i>Value in Health</i> , 2021, 24, 1845-1852.	0.1	6
16	Musculoskeletal health and capability wellbeing: Associations between the HAQ-DI, ICECAP-A and ICECAP-O measures in a population survey. <i>Musculoskeletal Science and Practice</i> , 2021, 55, 102420.	0.6	1
17	DLQI scoring improves the discriminatory power of the Dermatology Life Quality Index in patients with psoriasis, pemphigus and morphea. <i>British Journal of Dermatology</i> , 2020, 182, 1167-1175.	1.4	25
18	Acceptable health and ageing: results of a cross-sectional study from Hungary. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 346.	1.0	3

#	ARTICLE	IF	CITATIONS
19	Managing COVID-19 within and across health systems: why we need performance intelligence to coordinate a global response. <i>Health Research Policy and Systems</i> , 2020, 18, 80.	1.1	58
20	PMS1 MUSCULOSKELETAL HEALTH AND CAPABILITY OF WELL-BEING MEASURED BY THE ICECAP-A AND -ICECAP-O INSTRUMENTS. <i>Value in Health</i> , 2020, 23, S214.	0.1	0
21	Eliciting preferences for outpatient care experiences in Hungary: A discrete choice experiment with a national representative sample. <i>PLoS ONE</i> , 2020, 15, e0235165.	1.1	4
22	Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary. <i>Value in Health</i> , 2020, 23, 1235-1245.	0.1	58
23	PNS203 ICECAP-A AND ICECAP-O CAPABILITY OF WELL-BEING MEASURES: WHICH ONE TO USE IN AGE-GROUP 50-70?. <i>Value in Health</i> , 2020, 23, S321.	0.1	0
24	PMU10 A SCOPING REVIEW OF HEALTH ECONOMIC EVALUATIONS FROM THE MIDDLE EAST AND NORTH AFRICA REGION. <i>Value in Health</i> , 2020, 23, S234-S235.	0.1	0
25	Capability of well-being: validation of the Hungarian version of the ICECAP-A and ICECAP-O questionnaires and population normative data. <i>Quality of Life Research</i> , 2020, 29, 2863-2874.	1.5	13
26	PGI21 COST PER ACCEPTABLE LIFE-YEARS AND COST PER QALY GAINS IN NON-ACCEPTABLE HEALTH STATE FOR BIOLOGICAL TREATMENT IN CROHN'S DISEASE, A NOVEL APPROACH IN HEALTH ECONOMIC MODELLING. <i>Value in Health</i> , 2020, 23, S146.	0.1	0
27	Development of Population Tariffs for the CarerQoL Instrument for Hungary, Poland and Slovenia: A Discrete Choice Experiment Study to Measure the Burden of Informal Caregiving. <i>Pharmacoeconomics</i> , 2020, 38, 633-643.	1.7	6
28	Validity of EQ-5D-5L, Skindex-16, DLQI and DLQI-R in patients with hidradenitis suppurativa. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2584-2592.	1.3	25
29	Dermatology Life Quality Index (DLQI) score bands are applicable to DLQI-Relevant (DLQI-R) scoring. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e484-e486.	1.3	7
30	Did You Get What You Wanted? Patient Satisfaction and Congruence Between Preferred and Perceived Roles in Medical Decision Making in a Hungarian National Survey. <i>Value in Health Regional Issues</i> , 2020, 22, 61-67.	0.5	8
31	Exploring eHealth Literacy and Patient-Reported Experiences With Outpatient Care in the Hungarian General Adult Population: Cross-Sectional Study. <i>Journal of Medical Internet Research</i> , 2020, 22, e19013.	2.1	17
32	Health Economic Publications From the Middle East and North Africa Region: A Scoping Review of the Volume and Methods of Research. <i>Global Journal on Quality and Safety in Healthcare</i> , 2020, 3, 44-54.	0.1	10
33	Understanding the use of patient-reported data by health care insurers: A scoping review. <i>PLoS ONE</i> , 2020, 15, e0244546.	1.1	4
34	PNS251 Psychometric Properties of the Hungarian Language Version of the 13-ITEM Patient Activation Measure (PAM-13) in an Online Sample of the Adult General Population. <i>Value in Health</i> , 2020, 23, S683.	0.1	0
35	PMS6 Validation of the Musculoskeletal Health Questionnaire (MSK-HQ) for Hungary: Results of an Online CROSS-Sectional Survey Among the General Population. <i>Value in Health</i> , 2020, 23, S593.	0.1	0
36	PNS32 Towards a Healthcare Cost Catalogue for Middle EAST and North Africa: A Systematic Review of Productivity Loss Costs Reported in Health Economic Publications between 1989-2019. <i>Value in Health</i> , 2020, 23, S649.	0.1	2

#	ARTICLE	IF	CITATIONS
37	PNS24 Standardized Unit Cost Calculation for Informal Care Time and CROSS-Country Comparison: PECUNIA Project. Value in Health, 2020, 23, S647-S648.	0.1	0
38	PNS53 Population Normative DATA for the Health Assessment Questionnaire Disability INDEX in Hungary. Value in Health, 2020, 23, S652.	0.1	0
39	PNS38 Towards a Healthcare Cost Catalogue for Middle EAST and North Africa: A Systematic Review of Costs Reported in Health Economic Publications from Jordan, Lebanon Palestine and Syria 1995-2019. Value in Health, 2020, 23, S650.	0.1	1
40	PNS20 Towards a Healthcare Cost Catalogue for Middle EAST and North Africa: A Systematic Review of Costs Reported in Health Economic Publications from Egypt 1995-2019. Value in Health, 2020, 23, S647.	0.1	1
41	PNS19 Towards a Healthcare Cost Catalogue for Middle EAST and North Africa: A Systematic Review of Costs Reported in Health Economic Publications from Algeria, Libya, Morocco and Tunisia 1995-2019. Value in Health, 2020, 23, S647.	0.1	1
42	PNS34 Towards a Healthcare Cost Catalogue for Middle EAST and North Africa: A Systematic Review of Costs Reported in Health Economic Publications from the GULF Region 1995-2019. Value in Health, 2020, 23, S649.	0.1	1
43	Patient experiences in a public primary health care clinic: A South African case study. Society and Economy, 2020, 42, 333-347.	0.2	2
44	Title is missing!. , 2020, 15, e0235165.		0
45	Title is missing!. , 2020, 15, e0235165.		0
46	Title is missing!. , 2020, 15, e0235165.		0
47	Title is missing!. , 2020, 15, e0235165.		0
48	Title is missing!. , 2020, 15, e0235165.		0
49	Title is missing!. , 2020, 15, e0235165.		0
50	Understanding the use of patient-reported data by health care insurers: A scoping review. , 2020, 15, e0244546.		0
51	Understanding the use of patient-reported data by health care insurers: A scoping review. , 2020, 15, e0244546.		0
52	Understanding the use of patient-reported data by health care insurers: A scoping review. , 2020, 15, e0244546.		0
53	Understanding the use of patient-reported data by health care insurers: A scoping review. , 2020, 15, e0244546.		0
54	Validity of the <sc>EQ</sc> â€5D in patients with pemphigus vulgaris and pemphigus foliaceus. British Journal of Dermatology, 2019, 180, 802-809.	1.4	27

#	ARTICLE	IF	CITATIONS
55	Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 537-549.	0.7	19
56	Patient-assigned health utility values for controlled and uncontrolled pemphigus vulgaris and foliaceus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 2106-2113.	1.3	7
57	EQ-5D in patients with pemphigus vulgaris and pemphigus foliaceus. <i>British Journal of Dermatology</i> , 2019, 180, e126.	1.4	0
58	176 Measuring quality of life with the EQ-5D in patients with pemphigus vulgaris and pemphigus foliaceus. <i>Journal of Investigative Dermatology</i> , 2019, 139, S244.	0.3	0
59	Validity of the EQ-5D in pemphigus. <i>British Journal of Dermatology</i> , 2019, 180, e110.	1.4	0
60	Determinants of the acceptability of health problems in different ages: exploring a new application of the EQ VAS. <i>European Journal of Health Economics</i> , 2019, 20, 31-41.	1.4	6
61	Psychometric properties of the Hungarian version of the eHealth Literacy Scale. <i>European Journal of Health Economics</i> , 2019, 20, 57-69.	1.4	49
62	The burden of informal caregiving in Hungary, Poland and Slovenia: results from national representative surveys. <i>European Journal of Health Economics</i> , 2019, 20, 5-16.	1.4	22
63	Unmet medical needs in ambulatory care in Hungary: forgone visits and medications from a representative population survey. <i>European Journal of Health Economics</i> , 2019, 20, 71-78.	1.4	17
64	Towards a Central-Eastern European EQ-5D-3L population norm: comparing data from Hungarian, Polish and Slovenian population studies. <i>European Journal of Health Economics</i> , 2019, 20, 141-154.	1.4	12
65	Validity and reliability of the 9-item Shared Decision Making Questionnaire (SDM-Q-9) in a national survey in Hungary. <i>European Journal of Health Economics</i> , 2019, 20, 43-55.	1.4	25
66	Patient experiences with outpatient care in Hungary: results of an online population survey. <i>European Journal of Health Economics</i> , 2019, 20, 79-90.	1.4	10
67	A comparison of European, Polish, Slovenian and British EQ-5D-3L value sets using a Hungarian sample of 18 chronic diseases. <i>European Journal of Health Economics</i> , 2019, 20, 119-132.	1.4	17
68	Subjective expectations regarding ageing: a cross-sectional online population survey in Hungary. <i>European Journal of Health Economics</i> , 2019, 20, 17-30.	1.4	11
69	Patient and general population values for luminal and perianal fistulising Crohn's disease health states. <i>European Journal of Health Economics</i> , 2019, 20, 91-100.	1.4	5
70	Cost-of-illness studies in nine Central and Eastern European countries. <i>European Journal of Health Economics</i> , 2019, 20, 155-172.	1.4	23
71	Subjective well-being in patients with pemphigus: a path analysis. <i>European Journal of Health Economics</i> , 2019, 20, 101-107.	1.4	7
72	EQ-5D studies in nervous system diseases in eight Central and East European countries: a systematic literature review. <i>European Journal of Health Economics</i> , 2019, 20, 109-117.	1.4	8

#	ARTICLE	IF	CITATIONS
73	Time to revise the Dermatology Life Quality Index scoring in psoriasis treatment guidelines. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e267-e269.	1.3	19
74	PMU131 VALIDITY OF THE POLISH VERSION OF THE CARERQOL-7D QUESTIONNAIRE AMONG INFORMAL CAREGIVERS IN THE POLISH GENERAL POPULATION. Value in Health, 2019, 22, S731.	0.1	0
75	PMU139 VALIDITY OF THE SLOVENIAN VERSION OF THE CARERQOL-7D QUESTIONNAIRE AMONG INFORMAL CAREGIVERS IN THE SLOVENIAN GENERAL POPULATION. Value in Health, 2019, 22, S733.	0.1	0
76	PNS399 DEVELOPMENT OF POPULATION TARIFFS FOR THE CARER-QOL-7D INSTRUMENT FOR HUNGARY, POLAND AND SLOVENIA: A DISCRETE CHOICE EXPERIMENT STUDY TO MEASURE THE BURDEN OF INFORMAL CAREGIVING. Value in Health, 2019, 22, S833.	0.1	0
77	PNS393 POPULATION NORMS WITH THE ICECAP-A AND ICECAP-O CAPABILITY MEASURES IN HUNGARY. Value in Health, 2019, 22, S831-S832.	0.1	0
78	PNS398 THE ASSOCIATION BETWEEN EHEALTH-LITERACY, SHARED DECISION-MAKING AND HEALTH RISK BEHAVIOURS IN AN ONLINE SAMPLE OF THE HUNGARIAN GENERAL POPULATION. Value in Health, 2019, 22, S832-S833.	0.1	0
79	PNS401 THE FIRST PARALLEL EQ-5D-3L AND EQ-5D-5L COMPOSITE TIME TRADE-OFF VALUATION STUDY IN EUROPE. Value in Health, 2019, 22, S833.	0.1	1
80	PNS331 QUANTIFYING THE ACCEPTABILITY OF HEALTH PROBLEMS IN DIFFERENT AGES USING THE EQ-5D-3L INSTRUMENT. Value in Health, 2019, 22, S820.	0.1	1
81	PNS379 SUFFERING ALONE: UNMET NEEDS FOR INFORMAL CARE IN HUNGARY, POLAND AND SLOVENIA. Value in Health, 2019, 22, S829.	0.1	0
82	PNS197 WAITING TIMES FOR HEALTH CARE SERVICES IN HUNGARY - RESULTS OF A REPRESENTATIVE POPULATION SURVEY. Value in Health, 2019, 22, S794.	0.1	2
83	PNS389 VALIDITY OF THE HUNGARIAN TRANSLATION OF THE CARERQOL-7D INSTRUMENT AMONG INFORMAL CAREGIVERS IN THE HUNGARIAN GENERAL POPULATION. Value in Health, 2019, 22, S830-S831.	0.1	0
84	PNS397 PATIENTS' PERCEPTION OF THE QUALITY OF CONSULTATIONS MODELLED BY PATIENT-REPORTED EXPERIENCE AND HEALTH-RELATED QUALITY OF LIFE MEASURES. Value in Health, 2019, 22, S832.	0.1	1
85	Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn's disease. Quality of Life Research, 2019, 28, 141-152.	1.5	41
86	Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naïve Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis. Advances in Therapy, 2019, 36, 721-745.	1.3	7
87	Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations. Current Medicinal Chemistry, 2019, 26, 259-269.	1.2	34
88	Long-term care financing in Europe: An overview. Zdrowie Publiczne I Zarządzanie, 2019, 17, 131-145.	0.3	0
89	Implementation of Country-Wide Pharmacoeconomic Principles in Cancer Care in Developing Countries: Expert-Based Recommendations. Global Journal on Quality and Safety in Healthcare, 2019, 2, 109-114.	0.1	2
90	Quality of life in patients with atopic dermatitis. Cutis, 2019, 104, 174-177.	0.4	23

#	ARTICLE	IF	CITATIONS
91	Rationalizing the introduction and use of pharmaceutical products: The role of managed entry agreements in Central and Eastern European countries. <i>Health Policy</i> , 2018, 122, 230-236.	1.4	20
92	Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe. <i>United European Gastroenterology Journal</i> , 2018, 6, 310-321.	1.6	20
93	A detailed analysis of "not relevant" responses on the <scp>DLQI</scp> in psoriasis: potential biases in treatment decisions. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 783-790.	1.3	40
94	Is the DLQI appropriate for medical decision-making in psoriasis patients?. <i>Archives of Dermatological Research</i> , 2018, 310, 47-55.	1.1	24
95	PMS3 - INFLIXIMAB FOR DISEASE-MODIFYING ANTI-RHEUMATIC DRUG-NAIVE RHEUMATOID ARTHRITIS PATIENTS: SYSTEMATIC REVIEW AND DESCRIPTIVE ANALYSIS OF PUBLICATIONS OF RANDOMIZED CONTROLLED TRIALS. <i>Value in Health</i> , 2018, 21, S288.	0.1	1
96	PMU43 - THE COST OF INFORMAL CARE IN HUNGARY: A POOLED ANALYSIS OF 14 CROSS-SECTIONAL STUDIES. <i>Value in Health</i> , 2018, 21, S315.	0.1	0
97	PMU91 - USE OF EQ-5D IN CENTRAL AND EASTERN EUROPE 2000-2015: NEUROLOGICAL DISORDERS. <i>Value in Health</i> , 2018, 21, S323.	0.1	0
98	PMU126 - SUBJECTIVE EXPECTATIONS REGARDING FUTURE HEALTH, WELL-BEING AND HEALTHCARE COSTS IN HUNGARY. <i>Value in Health</i> , 2018, 21, S328.	0.1	0
99	PMS119 - ACCEPTABILITY OF HEALTH PROBLEMS IN CHRONIC MUSCULOSKELETAL DISEASES. <i>Value in Health</i> , 2018, 21, S308.	0.1	0
100	PSS60 - UTILITY ASSESSMENT FOR PEMPHIGUS HEALTH STATES USING VISUAL ANALOGUE SCALE AND TIME TRADE-OFF METHODS. <i>Value in Health</i> , 2018, 21, S433.	0.1	0
101	PRM185 - COMPARISON OF THE MEASUREMENT PROPERTIES OF THE EQ-5D-5L AND EQ-5D-3L IN PATIENTS WITH CROHN'S DISEASE. <i>Value in Health</i> , 2018, 21, S388.	0.1	0
102	PGI50 - HAPPY TOMORROW BUT GLOOMING ELDERLY? SELF-ESTIMATION OF FUTURE HEALTH IN CROHN'S DISEASE. <i>Value in Health</i> , 2018, 21, S150.	0.1	0
103	PRM171 - DETERMINANTS OF THE ACCEPTABILITY OF HEALTH PROBLEMS IN DIFFERENT AGES: EXPLORING A NEW APPLICATION OF THE EQ VAS. <i>Value in Health</i> , 2018, 21, S385.	0.1	0
104	PMU124 - DOES THE CHOICE OF EQ-5D-3L TARIFF MATTER FOR THE EVALUATION OF CHRONIC DISEASES? COMPARATIVE ANALYSIS OF THE POLISH, UK, SLOVENIAN AND EUROPEAN SCORES. <i>Value in Health</i> , 2018, 21, S328.	0.1	0
105	é“¶á±ç—...ä-DLQI æ-°è~,â^†á...-â¼çš,,æè®. <i>British Journal of Dermatology</i> , 2018, 179, e217-e217.	1.4	0
106	PMU90 - HEALTH PROBLEMS IN HUNGARIAN ELDERLY OUTPATIENTS MEASURED BY THE EQ-5D-3L: COMPARISON WITH A POPULATION NORM FOR CENTRAL EASTERN EUROPE. <i>Value in Health</i> , 2018, 21, S323.	0.1	1
107	Proposal of a new scoring formula for the Dermatology Life Quality Index in psoriasis. <i>British Journal of Dermatology</i> , 2018, 179, 1102-1108.	1.4	42
108	The Economic Impact of Biosimilars on Chronic Immune-Mediated Inflammatory Diseases. <i>Current Pharmaceutical Design</i> , 2018, 23, 6770-6778.	0.9	14

#	ARTICLE	IF	CITATIONS
109	EQ-5D studies in cardiovascular diseases in eight Central and Eastern European countries: a systematic review of the literature. <i>Kardiologia Polska</i> , 2018, 76, 860-870.	0.3	19
110	Exploring the Relationship between Quality of Life (EQ-5D) and Clinical Measures in Adult Attention Deficit Hyperactivity Disorder (ADHD). <i>Applied Research in Quality of Life</i> , 2017, 12, 409-424.	1.4	4
111	Comparing self-perceived and estimated fracture risk by FRAX [®] of women with osteoporosis. <i>Archives of Osteoporosis</i> , 2017, 12, 4.	1.0	3
112	The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries. <i>Advances in Therapy</i> , 2017, 34, 1128-1144.	1.3	64
113	Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 597-606.	0.7	22
114	015 The impact of pemphigus on health-related quality of life: First results with the EQ-5D questionnaire. <i>Journal of Investigative Dermatology</i> , 2017, 137, S195.	0.3	0
115	017 Women, elderly and less educated psoriasis patients provide more "not relevant" responses on the Dermatology Life Quality Index - is it a problem?. <i>Journal of Investigative Dermatology</i> , 2017, 137, S195.	0.3	0
116	Budget Impact Analysis Of Biosimilar Rituximab (CT-P10) For The Treatment Of Diffuse Large B-Cell And Follicular Lymphoma In The 28 EU Member States. <i>Value in Health</i> , 2017, 20, A548.	0.1	2
117	EQ-5D studies in musculoskeletal and connective tissue diseases in eight Central and Eastern European countries: a systematic literature review and meta-analysis. <i>Rheumatology International</i> , 2017, 37, 1957-1977.	1.5	9
118	Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients. <i>Quality of Life Research</i> , 2017, 26, 3409-3419.	1.5	51
119	Long-term costs and survival of prostate cancer: a population-based study. <i>International Urology and Nephrology</i> , 2017, 49, 1707-1714.	0.6	5
120	Bleeding out the quality-adjusted life years: evaluating the burden of primary dysmenorrhea using time trade-off and willingness-to-pay methods. <i>Pain</i> , 2017, 158, 2259-2267.	2.0	30
121	Estimating Survival After Radical Prostatectomy In Prostate Cancer; A Propensity-Score Matching Method. <i>Value in Health</i> , 2017, 20, A421.	0.1	0
122	Applicability Of The EQ-5D-3L Descriptive System To Explore Subjective Future Health Expectations. <i>Value in Health</i> , 2017, 20, A690.	0.1	0
123	Access to biologicals in Crohn's disease in ten European countries. <i>World Journal of Gastroenterology</i> , 2017, 23, 6294.	1.4	35
124	Determinants of biological drug survival in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years of retrospective data. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 139-147.	0.7	15
125	Subjective health expectations of patients with age-related macular degeneration treated with antiVEGF drugs. <i>BMC Geriatrics</i> , 2017, 17, 233.	1.1	17
126	A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 1-7.	0.7	44

#	ARTICLE	IF	CITATIONS
127	Alopecia areata and health-related quality of life: a systematic review and meta-analysis. British Journal of Dermatology, 2016, 175, 561-571.	1.4	144
128	Valuation of pemphigus vulgaris and pemphigus foliaceus health states: a convenience sample experiment. British Journal of Dermatology, 2016, 175, 593-599.	1.4	15
129	The changing landscape of biosimilars in rheumatology. Annals of the Rheumatic Diseases, 2016, 75, 974-982.	0.5	160
130	Eq-5d Studies In Nervous System Diseases In Eight Central And Eastern European Countries. Value in Health, 2016, 19, A471.	0.1	0
131	A Cost-Effectiveness Analysis of Biosimilar Infliximab (Inflixtra ^Ä) For The Treatment of Ankylosing Spondylitis In Nine European Countries. Value in Health, 2016, 19, A540.	0.1	0
132	A Cost-Effectiveness Analysis of Biosimilar Infliximab (Inflixtra ^Ä) For The Treatment of Psoriatic Arthritis In Nine European Countries. Value in Health, 2016, 19, A540-A541.	0.1	1
133	EQ-5D Studies in Rheumatology in Eight Central and Eastern European Countries. Value in Health, 2016, 19, A542.	0.1	1
134	Construct Validity Of The 10-Year Time Trade-Off Method In Psoriasis Patients. Value in Health, 2016, 19, A571.	0.1	1
135	EQ-5D Studies in Diseases of The Circulatory System in Eight Central and Eastern European Countries. Value in Health, 2016, 19, A657-A658.	0.1	0
136	Epidemiology and Survival in Prostate Cancer; A Population Based Study Analysing The Hungarian National Health Insurance Found Database. Value in Health, 2016, 19, A716.	0.1	0
137	Willingness To Pay For Primary Dysmenorrhea Health States. Value in Health, 2016, 19, A404-A405.	0.1	0
138	Social/economic costs and quality of life in patients with haemophilia in Europe. European Journal of Health Economics, 2016, 17, 53-65.	1.4	53
139	Perceived Risks Contra Benefits of Using Biosimilar Drugs in Ulcerative Colitis: Discrete Choice Experiment among Gastroenterologists. Value in Health Regional Issues, 2016, 10, 85-90.	0.5	11
140	017 Is it appropriate to use the Dermatology Life Quality Index for medical-decision making in Äpsoriasis patients?. Journal of Investigative Dermatology, 2016, 136, S163.	0.3	0
141	From representing views to representativeness of views: Illustrating a new (Q2S) approach in the context of health care priority setting in nine European countries. Social Science and Medicine, 2016, 166, 205-213.	1.8	19
142	EQ-5D in Central and Eastern Europe: 2000Ä2015. Quality of Life Research, 2016, 25, 2693-2710.	1.5	103
143	Measurement Properties of The EQ-5D-5l Compared To The EQ-5D-3l In Psoriasis Patients. Value in Health, 2016, 19, A572-A573.	0.1	0
144	Social/economic costs and health-related quality of life in patients with fragile X syndrome in Europe. European Journal of Health Economics, 2016, 17, 43-52.	1.4	35

#	ARTICLE	IF	CITATIONS
145	Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 89-98.	1.4	41
146	Patients' access to biological therapy in chronic inflammatory conditions; per capita GDP does not explain the intercountry differences. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 942-943.	0.5	21
147	Discrepancies between the Dermatology Life Quality Index and utility scores. <i>Quality of Life Research</i> , 2016, 25, 1687-1696.	1.5	16
148	Comparative analysis of decision maker preferences for equity/efficiency attributes in reimbursement decisions in three European countries. <i>European Journal of Health Economics</i> , 2016, 17, 791-799.	1.4	10
149	Treatment preferences of originator versus biosimilar drugs in Crohn's disease; discrete choice experiment among gastroenterologists. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 22-27.	0.6	30
150	A magánfinanszírozás helye a magyar egészségügyben; Forráshiányban az egészségügy "Mit tehetnek a biztosítók?". <i>Biztosítások és Kockázat</i> , 2016, 3, .	0.1	0
151	Social Utility Values for Pemphigus Vulgaris and Foliaceus: A Composite Time Trade-Off Study. <i>Value in Health</i> , 2015, 18, A673.	0.1	1
152	Time Trade-Off Utility Values in Mild and Severe Primary Dysmenorrhea. <i>Value in Health</i> , 2015, 18, A738-A739.	0.1	1
153	The impact of the recession on health care expenditure "How does the Czech Republic, Hungary, Poland and Slovakia compare to other OECD countries?". <i>Society and Economy</i> , 2015, 37, 73-88.	0.2	1
154	Use of biologics for psoriasis in Central and Eastern European countries. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2222-2230.	1.3	41
155	The Hungarian Care Managing Organization Pilot Program. <i>Value in Health Regional Issues</i> , 2015, 7, 27-33.	0.5	40
156	Does the Implementation of Official User Charges Help to Eradicate Informal Payments "Lessons to be Learnt from the Hungarian Experience. <i>Frontiers in Public Health</i> , 2015, 3, 181.	1.3	4
157	Health state utilities for migraine based on attack frequency: a time trade-off study. <i>Neurological Sciences</i> , 2015, 36, 197-202.	0.9	12
158	Cost of illness of medically treated benign prostatic hyperplasia in Hungary. <i>International Urology and Nephrology</i> , 2015, 47, 1241-1249.	0.6	11
159	Health-related quality of life and its determinants in pemphigus: a systematic review and meta-analysis. <i>British Journal of Dermatology</i> , 2015, 173, 1076-1080.	1.4	24
160	Health Related Quality of Life in Patients with Bladder Cancer: A Cross-Sectional Survey and Validation Study of the Hungarian Version of the Bladder Cancer Index. <i>Pathology and Oncology Research</i> , 2015, 21, 619-627.	0.9	17
161	Biosimilars for the management of rheumatoid arthritis: economic considerations. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 43-52.	1.3	83
162	Moderate to severe psoriasis patients' subjective future expectations regarding health-related quality of life and longevity. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1398-1405.	1.3	21

#	ARTICLE	IF	CITATIONS
163	Nem diabeteses perifériás neuropathiás betegek életminőségének mérése magyarországi háziorvosi praxisokban végzett keresztmetszeti vizsgálat eredményei alapján. Ideggyógyászati Szemle, 2015, 68, 325-330.	0.4	3
164	Biological therapy in inflammatory bowel diseases: Access in Central and Eastern Europe. World Journal of Gastroenterology, 2015, 21, 1728.	1.4	64
165	QUALITY OF LIFE OF PATIENTS WITH NON-DIABETIC PERIPHERAL NEUROPATHIC PAIN; RESULTS FROM A CROSS-SECTIONAL SURVEY IN GENERAL PRACTICES IN HUNGARY. Ideggyógyászati Szemle, 2015, 68, 325-30.	0.4	2
166	Health status and quality of life in patients with psoriasis: an Iranian cross-sectional survey. Archives of Iranian Medicine, 2015, 18, 153-9.	0.2	19
167	Quality of Life and Costs in Parkinson's Disease: A Cross Sectional Study in Hungary. PLoS ONE, 2014, 9, e107704.	1.1	31
168	Subjective expectations regarding length and health-related quality of life in Hungary: results from an empirical investigation. Health Expectations, 2014, 17, 696-709.	1.1	24
169	Subjective health expectations at biological therapy initiation: a survey of rheumatoid arthritis patients and rheumatologists. European Journal of Health Economics, 2014, 15, 83-92.	1.4	20
170	Acceptability of less than perfect health states in rheumatoid arthritis: the patients' perspective. European Journal of Health Economics, 2014, 15, 73-82.	1.4	12
171	Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries. European Journal of Health Economics, 2014, 15, 35-43.	1.4	33
172	Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics. European Journal of Health Economics, 2014, 15, 121-128.	1.4	41
173	Health Related Quality of Life of Patients and Their Caregivers In Rare Diseases Results of the Burqol-Rd Project In Hungary. Value in Health, 2014, 17, A538.	0.1	4
174	Health-Related Quality Of Life And Subjective Happiness Of Patients With Benign Prostatic Hyperplasia: First Results Of A Cross-Sectional Survey From Hungary. Value in Health, 2014, 17, A471-A472.	0.1	0
175	Fidaxomicin Therapy for Patients with Clostridium Difficile Infection: A Systematic Literature Review and Meta-Analysis. Value in Health, 2014, 17, A665.	0.1	1
176	The link between past informal payments and willingness of the Hungarian population to pay formal fees for health care services: results from a contingent valuation study. European Journal of Health Economics, 2014, 15, 853-867.	1.4	13
177	Biological and biosimilar therapies in inflammatory conditions: challenges for the Central and Eastern European countries. European Journal of Health Economics, 2014, 15, 1-4.	1.4	9
178	Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria. European Journal of Health Economics, 2014, 15, 13-25.	1.4	70
179	Transferability of results of cost utility analyses for biologics in inflammatory conditions for Central and Eastern European countries. European Journal of Health Economics, 2014, 15, 27-34.	1.4	14
180	Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis. European Journal of Health Economics, 2014, 15, 45-52.	1.4	27

#	ARTICLE	IF	CITATIONS
181	Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison. <i>European Journal of Health Economics</i> , 2014, 15, 53-64.	1.4	26
182	Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres. <i>European Journal of Health Economics</i> , 2014, 15, 101-109.	1.4	22
183	Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary. <i>European Journal of Health Economics</i> , 2014, 15, 111-119.	1.4	60
184	HTA in Central and Eastern European countries; the 2001: A Space Odyssey and efficiency gain. <i>European Journal of Health Economics</i> , 2014, 15, 675-680.	1.4	7
185	The state of the art in European research on reducing social exclusion and stigma related to mental health: A systematic mapping of the literature. <i>European Psychiatry</i> , 2014, 29, 381-389.	0.1	110
186	Exploring consumers' attitudes towards informal patient payments using the combined method of cluster and multinomial regression analysis - the case of Hungary. <i>BMC Health Services Research</i> , 2013, 13, 62.	0.9	33
187	Health Related Quality of Life of Patients with Bladder Cancer in Hungary. <i>Value in Health</i> , 2013, 16, A635.	0.1	0
188	Prioritization Preferences among General Practitioners in Hungary. <i>East European Politics and Societies</i> , 2012, 26, 20-32.	0.7	1
189	Comparing cost-sharing practices for pharmaceuticals and health care services among four central European countries. <i>Society and Economy</i> , 2012, 34, 221-240.	0.2	9
190	Preferences of Hungarian consumers for quality, access and price attributes of health care services – result of a discrete choice experiment. <i>Society and Economy</i> , 2012, 34, 293-311.	0.2	7
191	Health economics and health technology assessment in Central and Eastern Europe: a dose of reality. <i>European Journal of Health Economics</i> , 2012, 13, 525-531.	1.4	27
192	Changes in Equity in Out-of-pocket Payments during the Period of Health Care Reforms: Evidence from Hungary. <i>International Journal for Equity in Health</i> , 2012, 11, 36.	1.5	36
193	PND60 Non-Diabetic Peripheral Neuropathic Pain is Underdiagnosed in GP Practices Although it has High Impact on Patients' Health Related Quality of Life. <i>Value in Health</i> , 2012, 15, A556-A557.	0.1	0
194	Informal payments for healthcare services and short-term effects of the introduction of visit fee on these payments in Hungary. <i>International Journal of Health Planning and Management</i> , 2012, 27, 63-79.	0.7	48
195	Health status and costs of ambulatory patients with multiple sclerosis in Hungary. <i>Ideggyogyaszati Szemle</i> , 2012, 65, 316-24.	0.4	7
196	PMS56 Subjective Health Expectations of Rheumatoid Arthritis Patients Starting Biological Therapy. <i>Value in Health</i> , 2011, 14, A312-A313.	0.1	0
197	PHP3 Patient Preferences Considering the Choice of Health Care Providers in Hungary – Results From Discrete Choice Experiment. <i>Value in Health</i> , 2011, 14, A333-A334.	0.1	0
198	User fees for public health care services in Hungary: Expectations, experience, and acceptability from the perspectives of different stakeholders. <i>Health Policy</i> , 2011, 102, 255-262.	1.4	44

#	ARTICLE	IF	CITATIONS
199	The economic impact of dementia in Europe in 2008â€”cost estimates from the Eurocode project. <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 825-832.	1.3	158
200	The disease burden of colorectal cancer in Hungary. <i>European Journal of Health Economics</i> , 2010, 10, 35-40.	1.4	18
201	Future challenges for health economics and health technology assessment of biological drugs. <i>European Journal of Health Economics</i> , 2010, 11, 235-238.	1.4	6
202	Costs of dementia in Hungary. <i>Journal of Nutrition, Health and Aging</i> , 2010, 14, 633-639.	1.5	30
203	Cost-of-illness of patients with systemic sclerosis in a tertiary care centre. <i>Rheumatology</i> , 2010, 49, 1920-1928.	0.9	47
204	PMS56 ACCESS TO BIOLOGIC TREATMENT IN RHEUMATOID ARTHRITIS IN CENTRAL AND EASTERN EUROPEAN (CEE) COUNTRIES. <i>Value in Health</i> , 2010, 13, A133.	0.1	0
205	PCV35 SEASONAL VARIATION AND INFLUENCE OF METEOROLOGICAL FACTORS IN CASE OF ACUTE CEREBROVASCULAR EVENTS. <i>Value in Health</i> , 2010, 13, A155.	0.1	0
206	PND9 ASSESSMENT OF DISEASE BURDEN ASSOCIATED WITH EPILEPSY IN HUNGARY, BASED ON A CROSS-SECTIONAL QUESTIONNAIRE SURVEY OF 100 PATIENTS. <i>Value in Health</i> , 2010, 13, A389.	0.1	0
207	PHP129 ATTITUDES OF HUNGARIAN POPULATION TOWARD CO-PAYMENTS. <i>Value in Health</i> , 2010, 13, A428.	0.1	0
208	Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: results from a cross-sectional survey. <i>Scandinavian Journal of Rheumatology</i> , 2010, 39, 303-309.	0.6	45
209	Adherence to biologic DMARD therapies in rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 1367-1378.	1.4	60
210	Challenges in economic evaluation of new drugs: experience with rituximab in Hungary. <i>Medical Science Monitor</i> , 2010, 16, SR1-5.	0.5	7
211	History of health technology assessment in Hungary. <i>International Journal of Technology Assessment in Health Care</i> , 2009, 25, 120-126.	0.2	24
212	Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment. <i>Rheumatology International</i> , 2009, 30, 199-205.	1.5	36
213	Quality management and patient safety: Survey results from 102 Hungarian hospitals. <i>Health Policy</i> , 2009, 90, 175-180.	1.4	26
214	Budget-Impact Analyses. <i>Pharmacoeconomics</i> , 2009, 27, 807-827.	1.7	38
215	PMS83 COMPARISON OF A GENERIC UTILITY MEASURE (EQ-5D) AND DISEASE SPECIFIC QUALITY OF LIFE INSTRUMENTS IN PSORIATIC ARTHRITIS AND RHEUMATOID ARTHRITIS. <i>Value in Health</i> , 2009, 12, A449.	0.1	0
216	PMS27 COSTS OF PSORIATIC ARTHRITIS IN HUNGARY; RESULTS FROM A CROSS-SECTIONAL SURVEY. <i>Value in Health</i> , 2009, 12, A68.	0.1	0

#	ARTICLE	IF	CITATIONS
217	PHP35 THE EFFECT OF THE WITHDRAWAL OF HOSPITAL DAILY FEE ON THE NUMBER OF ADMISSIONS TO ACUTE CARE HOSPITAL WARDS IN HUNGARY. Value in Health, 2009, 12, A85.	0.1	0
218	PMH15 COSTS OF DEMENTIA IN HUNGARY. Value in Health, 2009, 12, A175.	0.1	0
219	PHP82 ASSESSMENT OF LIFESPAN AND HEALTH STATUS EXPECTATIONS IN HUNGARY; RESULTS OF A WEB-SURVEY. Value in Health, 2009, 12, A252.	0.1	0
220	PMH67 QUALITY OF LIFE OF OUTPATIENT DEMENTED PATIENTS IN HUNGARY. Value in Health, 2009, 12, A363.	0.1	0
221	PDB66 PAYING FOR COSTLY PHARMACEUTICALSâ€”REIMBURSEMENT STATUS OF LONG-ACTING INSULIN ANALOGUES IN SELECTED DEVELOPED COUNTRIES. Value in Health, 2009, 12, A414.	0.1	1
222	Colorectal cancer screening policy in Hungary. International Journal of Technology Assessment in Health Care, 2009, 25, 109-110.	0.2	3
223	Epidemiology of osteoporosis related fractures in Hungary from the nationwide health insurance database, 1999â€”2003. Osteoporosis International, 2008, 19, 243-249.	1.3	60
224	Efficacy of adalimumab, etanercept, and infliximab in psoriatic arthritis based on ACR50 response after 24 weeks of treatment. Scandinavian Journal of Rheumatology, 2008, 37, 399-400.	0.6	11
225	PMS71 A COST-EFFECTIVENESS ASSESSMENT OF ABATACEPT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN HUNGARY. Value in Health, 2008, 11, A549-A550.	0.1	0
226	PHP64 THE EFFECT OF THE PERFORMANCE VOLUME LIMIT (PVL) ON THE DRG FINANCING OF THE HUNGARIAN HOSPITALS. Value in Health, 2008, 11, A48.	0.1	2
227	PCN90 EFFECT OF THE HUNGARIAN ORGANIZED NATIONWIDE CERVICAL CANCER SCREENING PROGRAMME ON THE COVERAGE OF WOMEN UNDER THE AGE OF 25 YEARS. Value in Health, 2008, 11, A81-A82.	0.1	0
228	PCV46 COSTS OF ACUTE MYOCARDIAL INFARCTION IN HUNGARY; 2003-2005. Value in Health, 2008, 11, A200.	0.1	0
229	PCV103 THE PATIENT SAFETY STANDARDS OF ACUTE STROKE MANAGEMENT IN HUNGARY. Value in Health, 2008, 11, A217.	0.1	1
230	PMS2 COMPARATIVE EFFICACY OF BIOLOGICAL TREATMENTS IN PATIENTS WITH PSORIATIC ARTHRITIS; SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS. Value in Health, 2008, 11, A254-A255.	0.1	0
231	PMS4 THE EFFECT OF HOSPITAL VOLUME ON 30 DAYS MORTALITY FOLLOWING HIP FRACTURE. Value in Health, 2008, 11, A255.	0.1	0
232	PMS23 MODELLING OF BURDEN OF FEMORAL NECK FRACTURE IN 2007 FROM PURCHASER'S POINT OF VIEW. Value in Health, 2008, 11, A261.	0.1	0
233	PSS2 EFFICACY OF BIOLOGICAL TREATMENT IN PATIENTS WITH PSORIASIS; META-ANALYSIS. Value in Health, 2008, 11, A284-A285.	0.1	0
234	PHP37 THE MARKET SHARE OF PRIVATE FOR-PROFIT AND NONPROFIT HEALTH CARE PROVIDERS FROM THE HUNGARIAN HEALTH INSURANCE BUDGET. Value in Health, 2007, 10, A33.	0.1	0

#	ARTICLE	IF	CITATIONS
235	PCN39 GAP BETWEEN INPATIENT TREATMENT COST OF AND MORTALITY DUE TO BREAST CANCER IN HUNGARY. Value in Health, 2007, 10, A135.	0.1	1
236	PAR24 COST-UTILITY ANALYSIS OF RITUXIMAB TREATMENT IN RHEUMATOID ARTHRITIS AFTER ANTI-TNF-ALFATHERAPY IN HUNGARY. Value in Health, 2007, 10, A250.	0.1	0
237	PUK9 HEALTH STATUS AND COSTS OF PATIENTS UNDERGOING HAEMODIALYSISTREATMENT IN HUNGARY. Value in Health, 2007, 10, A315-A316.	0.1	0
238	PUK18 INCREASING MARKET SHARE OF PRIVATE DIALYSIS CENTRES FROM HEALTH INSURANCE EXPENDITURES IN HUNGARY. Value in Health, 2007, 10, A318.	0.1	0
239	PCN52 GAP BETWEEN TREATMENT COST OF AND MORTALITY DUE TO CERVICAL CANCER IN HUNGARY. Value in Health, 2007, 10, A338.	0.1	0
240	PHP3 BUDGET SILO MENTALITY BEHIND THE FORMER IRON CURTAIN:A CASE STUDY FROM HUNGARY. Value in Health, 2007, 10, A361.	0.1	0
241	POS2 CORRELATION BETWEEN PREDICTORS AND SUBSEQUENT SURGICAL MANAGEMENT FOLLOWING INTERNAL FIXATION OF FEMORAL NECK FRACTURES. Value in Health, 2007, 10, A393-A394.	0.1	0
242	POS3 THE ROLE OF SURGICAL DELAY ON EARLY MORTALITY IN PATIENTS WITH FEMORAL NECK FRACTURE. Value in Health, 2007, 10, A394.	0.1	0
243	PCV16 HEALTH INSURANCE COSTS OF STROKE HOSPITAL TREATMENTS IN HUNGARY; 2003-2005. Value in Health, 2007, 10, A410.	0.1	0
244	The time for cost-effectiveness in the new European Union member states: the development and role of health economics and technology assessment in the mirror of the Hungarian experience. European Journal of Health Economics, 2007, 8, 83-88.	1.4	15
245	Costs of rheumatoid arthritis in Hungary. Journal of Rheumatology, 2007, 34, 1437.	1.0	27
246	PHP17 EFFICIENCY OF RHEUMATOLOGY HOSPITAL CARE: CHANGES IN THE AVERAGE LENGTH OF STAY IN RHEUMATOLOGY DEPARTMENTS IN HUNGARY. Value in Health, 2006, 9, A212-A213.	0.1	0
247	PDB41 EFFECT OF COMPLICATIONS ON HEALTH RELATED QUALITY OF LIFE IN HUNGARIAN INSULIN TREATED DIABETIC PATINETS. Value in Health, 2006, 9, A237.	0.1	0
248	POS10 OSTEOPOROSIS RELATED HEALTH CARE UTILISATION IN HUNGARY BY THE NATIONWIDE HEALTH INSURANCE DATABASE. Value in Health, 2006, 9, A381.	0.1	0
249	POS15 CHANGES IN THE HEALTH STATUS AFTER FEMORAL NECK FRACTURE MEASURED BY EQ-5D. Value in Health, 2006, 9, A383.	0.1	0
250	The implementation of quality management systems in hospitals: a comparison between three countries. BMC Health Services Research, 2006, 6, 50.	0.9	39
251	Patients??? Preferences for Healthcare System Reforms in Hungary. Applied Health Economics and Health Policy, 2006, 5, 189-198.	1.0	20
252	PAR17 BURDEN OF ILLNESS, COSTS AND OUTCOMES OF RHEUMATOID ARTHRITIS IN HUNGARY. Value in Health, 2005, 8, A29.	0.1	3

#	ARTICLE	IF	CITATIONS
253	PHPI8 INTRODUCING THE "FOURTH HURDLE"™ IN THE NEW EUROPEAN UNION MEMBER STATES: THE CASE OF HUNGARY. Value in Health, 2004, 7, 714.	0.1	0
254	Issues for countries considering introducing the "fourth hurdle": The case of Hungary. International Journal of Technology Assessment in Health Care, 2004, 20, 337-341.	0.2	30
255	Pricing and reimbursement of drugs and medical devices in Hungary. European Journal of Health Economics, 2002, 3, 271-278.	1.4	17
256	Risk-adjusted infection rates in surgery: a model for outcome measurement in hospitals developing new quality improvement programmes. Journal of Hospital Infection, 2000, 44, 43-52.	1.4	22
257	Hospital Infection Prevention and Control: A Model for Improving the Quality of Hospital Care in Low- and Middle-Income Countries. Infection Control and Hospital Epidemiology, 1998, 19, 125-135.	1.0	26
258	Hospital Infection Prevention and Control: A Model for Improving the Quality of Hospital Care in Low- and Middle-Income Countries. Infection Control and Hospital Epidemiology, 1998, 19, 125-135.	1.0	13
259	Quality assurance in Hungarian hospitals: a new focus for management development. The Journal of Health Administration Education, 1994, 12, 551-8.	0.5	0
260	A biolÄ³giai terÄ³pia egÄ³szsÄ³ggazdasÄ³gi vonatkozÄ³sai. Magyar TudomÄ³ny, 0, , .	0.0	0
261	Az egÄ³szsÄ³gÄ¼gy finanszÄ³rozÄ³sÄ³jnak fenntarthatÄ³sÄ³ga. Magyar TudomÄ³ny, 0, , .	0.0	1